Q-omics provides the consensus-scored MECOM-AS1 profile across patient tissues and cancer cell-line models. MECOM-AS1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MECOM-AS1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MECOM-AS1 RNA expression shows 14,129 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRP, KIRC, and CCRCC as cancer lineages where MECOM-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MECOM-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MECOM-AS1 survival associations across molecular data types. MECOM-AS1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MECOM-AS1 RNA expression–survival associations across cancer types. High MECOM-AS1 expression shows unfavorable associations in KIRP, UVM and PAAD, but favorable associations in KIRC, UCS and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MECOM-AS1 RNA expression.
This table summarizes MECOM-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MECOM-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MECOM-AS1 shows lower tumor expression in KIRC, KIRP, KICH, LUAD, HNSC and BRCA. The KIRC box plot shows higher MECOM-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.418, t-test p < 0.001).
This table shows molecular features associated with MECOM-AS1 in patient tissues and cancer cell lines. In patient samples, MECOM-AS1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
